Edwards Lifesciences Corporation
EW
$76.04
$0.911.21%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -87.44% | 738.33% | 4.09% | -4.87% | -3.90% |
| Total Depreciation and Amortization | 23.48% | -12.88% | 2.86% | 4.90% | -0.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.31% | -36,464.89% | -186.24% | 120.22% | -2,936.84% |
| Change in Net Operating Assets | -167.74% | 2,834.40% | 94.50% | -110.46% | -1,671.31% |
| Cash from Operations | -136.24% | -5.30% | 794.39% | -139.17% | -66.80% |
| Capital Expenditure | 4.05% | 39.23% | -30.78% | 26.05% | -59.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 60.95% | -- | -- | -- | -- |
| Divestitures | -100.00% | -- | -- | -- | -- |
| Other Investing Activities | 44.25% | -295.15% | 63.71% | 127.66% | -60.91% |
| Cash from Investing | -121.35% | 2,064.82% | 97.78% | 347.52% | -84.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.10% | -36.46% | -12.56% | 87.05% | -2.35% |
| Repurchase of Common Stock | 99.99% | -533.14% | -78,950.00% | 99.96% | -157.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.98% | -241.67% | 3,700.00% | -110.00% | 168.97% |
| Cash from Financing | 102.93% | -911.08% | -256.56% | 114.93% | -188.35% |
| Foreign Exchange rate Adjustments | 199.03% | -275.17% | 203.09% | 385.29% | -136.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -130.84% | 371.99% | 429.75% | 130.46% | -172.57% |